We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.00 | 0.56% | 1,799.00 | 1,805.00 | 1,807.00 | 1,807.00 | 1,763.00 | 1,786.00 | 466,727 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.78 | 3.99B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/8/2018 07:38 | Our performance in the first half exceeded our expectations and we are pleased to be able to raise our guidance for both our Injectables and Generics businesses for the full year. | broadwood | |
15/8/2018 07:17 | Results far and away better than expected. Been accumulating (selling peaks buying troughs) for a while. Holding tight now for the time being. £20ps a likely possibility imo. imho, dyor etc etc | bantam175 | |
15/8/2018 07:06 | Wish I'd bought more when under a tenner. Hindsight... | richtea2517 | |
14/8/2018 22:58 | Should prove how wrong was Numis. | karateboy | |
14/8/2018 21:46 | wonder what tomorrow will bring | eentweedrie | |
13/8/2018 19:21 | A few decent buys at the close hope they haven't had the nod | joshuam | |
10/8/2018 10:16 | I like Hikma long term but I don't hold any stock through results after a few bitter experiences where stops have been useless. So I'll sell next week and re buy when I see the right chart spot. If I miss a big rise on results day - es la vida! | jgoold | |
09/8/2018 12:50 | Interims next wednesday will send us off with the correct information. After a rocky period the Company now seems more focused on what it is doing and the share price believes it is doing it well. | chrisgail | |
07/8/2018 14:00 | £17 breached - what a roller coaster but pleased I stayed with it. Suet | suetballs | |
01/8/2018 07:07 | I agree . Next stop is £20. | karateboy | |
01/8/2018 00:01 | Agree....I still think HIK will head back up to £20 .....by end of the year ...imo | gerrym two | |
31/7/2018 19:34 | Very strange trading pattern today. Shares drops lunch time to negative territory, then picks up at 15:00 to 1660p and closes at 1641p. Let's see if there is an RNS tomorrow. | karateboy | |
20/7/2018 08:30 | Upward trend for past 3 months since Teva chap and co. Joined | r ball | |
20/7/2018 08:20 | up almost 10% in a few days! | eentweedrie | |
19/7/2018 20:15 | We may be on the way to £20 having finally broken back of £15.! | karateboy | |
19/7/2018 14:46 | Won't hurt HIK to have a few brownie points with the FDA either. | bantam175 | |
19/7/2018 12:53 | I suppose this is what a drug shortage does.... | r ball | |
09/7/2018 09:51 | Someone is after our shares hold firm | joshuam | |
01/6/2018 05:56 | The main factor here is Indian drug manufacturers, and FDA.If you don't understand this you should not be invested. | r ball | |
30/5/2018 16:31 | Not a related issue imo. | bantam175 | |
30/5/2018 10:26 | RNS: "London, 30 May 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine(R) .(1) Methylergonovine Maleate Tablets are a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage." ----------------- Why on earth this has caused the share price to tank is just beyond me... j | jswjsw | |
25/5/2018 10:11 | Starting to move up ! | gerrym two | |
23/5/2018 16:28 | Cheers for the encouragement, almost back to yesterday at end of the day. | vas007 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions